Collegium Pharmaceutical ... (COLL)
NASDAQ: COLL
· Real-Time Price · USD
34.56
-0.09 (-0.26%)
At close: Sep 26, 2025, 1:37 PM
Collegium Pharmaceutical Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Belbuca Revenue | 52.6M | 51.66M | 107.41M | 53.2M | 52.2M | 50.66M | 94.75M | 45.45M | 43.14M | 44.21M | 42.05M | 38.8M | 42.3M | 3.31M | 8.73M |
| Belbuca Revenue Growth | +1.82% | -51.91% | +101.91% | +1.91% | +3.03% | -46.53% | +108.48% | +5.36% | -2.43% | +5.15% | +8.37% | -8.27% | +1177.98% | -62.10% | n/a |
| Nucynta ER Revenue | 19.95M | 19.69M | 36.81M | 19.77M | 19.27M | 19.19M | 42.35M | 22.63M | 19.17M | 21.14M | 18.95M | 17.13M | 17.08M | 19.26M | 13.37M |
| Nucynta ER Revenue Growth | +1.32% | -46.52% | +86.15% | +2.60% | +0.45% | -54.69% | +87.09% | +18.06% | -9.30% | +11.57% | +10.58% | +0.33% | -11.35% | +44.09% | n/a |
| Nucynta IR Revenue | 26.5M | 27.42M | 49.42M | 25.36M | 25.2M | 25.96M | 52.09M | 24.91M | 28.16M | 27.9M | 28.89M | 27.27M | 26.55M | 29.34M | n/a |
| Nucynta IR Revenue Growth | -3.34% | -44.52% | +94.86% | +0.63% | -2.92% | -50.17% | +109.16% | -11.55% | +0.93% | -3.45% | +5.94% | +2.71% | -9.48% | n/a | n/a |
| Symproic Revenue | 3.72M | 2.81M | 8.29M | 3.52M | 4.03M | 3.3M | 9.01M | 3.92M | 3.84M | 3.65M | 4.53M | 3.58M | 3.86M | 300K | n/a |
| Symproic Revenue Growth | +32.22% | -66.03% | +135.60% | -12.77% | +22.14% | -63.35% | +129.68% | +2.24% | +5.07% | -19.35% | +26.45% | -7.25% | +1186.67% | n/a | n/a |
| Xtampza ER Revenue | 52.6M | 47.64M | 96.03M | 49.49M | 44.57M | 45.81M | 88.26M | 39.8M | 41.24M | 47.87M | 35.24M | 38.86M | 33.19M | 31.52M | n/a |
| Xtampza ER Revenue Growth | +10.42% | -50.39% | +94.02% | +11.04% | -2.71% | -48.09% | +121.76% | -3.50% | -13.84% | +35.85% | -9.32% | +17.08% | +5.30% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 73.64M | 76.42M | 63.09M | 61.95M | 43.34M | 41.98M | 32.94M | 35.3M | 38.19M | 52.77M | 38.03M | 38.37M | 41.25M | 54.53M | 26.6M | 30.51M | 30.37M | 31.48M | 26.82M | 26.43M | 29.32M | 31.26M | 25.09M | 30.07M | 28.93M | 32.35M | 30.45M | 33.45M | 31.28M | 31.58M | 25.09M | 22.76M | 22.06M | 22.85M | 25.37M | 23.57M | 20.17M | 11.53M | 7.91M | 5.91M | 2.93M | 2.19M |
| Selling, General, and Administrative Revenue Growth | -3.65% | +21.13% | +1.83% | +42.97% | +3.22% | +27.44% | -6.67% | -7.58% | -27.63% | +38.76% | -0.89% | -6.99% | -24.34% | +104.98% | -12.82% | +0.48% | -3.52% | +17.34% | +1.51% | -9.88% | -6.20% | +24.59% | -16.57% | +3.93% | -10.56% | +6.24% | -8.96% | +6.93% | -0.96% | +25.88% | +10.24% | +3.15% | -3.44% | -9.93% | +7.64% | +16.82% | +75.04% | +45.79% | +33.82% | +101.33% | +34.28% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -3.98M | n/a | n/a | 3.98M | 1.61M | 1.45M | 3.46M | 2.93M | 2.47M | 2.14M | 2.49M | 2.67M | 2.4M | 2.49M | 2.46M | 2.99M | 2.25M | 1.91M | 2.24M | 2.27M | 2.19M | 2.07M | 2.18M | 2.13M | 3.33M | 3.25M | 4.3M | 4.06M | 1.53M | 3.36M | 1.64M | 1.45M |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | n/a | n/a | -100.00% | +147.55% | +10.97% | -58.12% | +18.16% | +18.53% | +15.46% | -14.12% | -6.49% | +11.18% | -3.73% | +1.30% | -17.81% | +33.04% | +17.93% | -14.75% | -1.37% | +3.37% | +6.04% | -5.05% | +2.30% | -36.06% | +2.37% | -24.34% | +5.88% | +165.32% | -54.41% | +104.63% | +13.56% | n/a |